Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study (Q38297438)

1 September 2017

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study (English)

1 reference

1 September 2017

0 references

12

Joseph L Witztum

1 reference

1 September 2017

1

Sotirios Tsimikas

1 reference

1 September 2017

9

Santica M Marcovina

1 reference

1 September 2017

11

Rosanne M Crooke

1 reference

1 September 2017

8

Qingqing Yang

1 reference

1 September 2017

2

Nicholas J Viney

1 reference

1 September 2017

6

Brenda F Baker

1 reference

1 September 2017

Steven G Hughes

3

1 reference

1 September 2017

Walter Singleton

4

1 reference

1 September 2017

Mark J Graham

5

1 reference

1 September 2017

Jennifer L Burkey

7

1 reference

1 September 2017

Richard S Geary

10

1 reference

1 September 2017

language of work or name

English

0 references

publication date

22 July 2015

1 reference

1 September 2017

1 reference

1 September 2017

386

1 reference

1 September 2017

1472-1483

1 reference

1 September 2017

10002

1 reference

Lipoprotein(a): resurrected by genetics

1 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Mechanisms of Lipoprotein(a) Pathogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Genetically elevated lipoprotein(a) and increased risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Genetic associations with valvular calcification and aortic stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Evidence mounts for a role of the kidney in lipoprotein(a) catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein(a) for risk assessment in patients with established coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Niacin in cardiovascular prevention: mechanisms, efficacy, and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Factor XI antisense oligonucleotide for prevention of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961252-1

7 January 2021

10.1016/S0140-6736(15)61252-1

Identifiers

DOI

1 reference

1 September 2017

1 reference